Clinical trials: Alcoholic Cirrhosis
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
Hepatic Encephalopathy, Cirrhosis
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Investigating the impact of hepatic encephalopathy on default mode networks within the brain to provide more clues with understanding the physiology of consciousness and predicting the reversibility of comatose states.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
- Trial name
- NCT02083367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
Non-alcoholic Steatohepatitis
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis
This study aims at evaluating and comparing the protective outcomes of using Obeticholic acid versus Vitamin E in NASH patients without cirrhosis.
- Trial name
- NCT05573204
- Testing
- Obeticholic Acid Oral Tablet, Vit E
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Tanta University
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04895943
- Testing
- bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- University Hospital Ostrava
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
The primary objective of this study is to assess the clinical performance of LIVERFAStTM In Vitro Diagnostic (IVD) Tests (Fibrosis score, Activity score and Steatosis score) in NAFLD suspected patients for staging of fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04579874
- Testing
- LIVERFASt
- Where
- 8 sites in United States
- Volunteers
- 241 people
- Sponsor
- Fibronostics USA, Inc
NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease )
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth…
- Conditions
- NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis
- Trial name
- COMET cohort (NCT07241195)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis
Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)
Objective of the study Our working hypothesis is that platelets activated by gut-derived metabolites dock in the liver of NAFLD patients and amplify the inflammatory state by releasing pro-inflammatory cytokines/chemokines, which…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Control Condition
- Trial name
- NCT06623084
- Testing
- Platelets characterization
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Stefania Basili
Non-alcoholic Fatty Liver Disease
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00641524
- Testing
- Phlebotomy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Western Ontario, Canada
Non-Alcoholic Fatty Liver Disease, Childhood Obesity
Clinical Epidemiology of NAFLD in Children and Adolescents
Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing alongside overweight and obesity, not only in adults but also in children and adolescents.
- Trial name
- LiverKids (NCT05526274)
- Testing
- Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
- Where
- Spain
- Volunteers
- 2,866 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Alcohol; Liver
Integrating Care for Patients With Alcohol Liver Disease and Alcohol Use Disorders
Alcohol related liver disease (ALD) contributes to 50% cases of cirrhosis worldwide and is the leading indication for liver transplant in North America.
- Trial name
- NCT05375682
- Testing
- Integrated care program
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Manitoba